According to a new report, published by KBV research, The Global Organ-on-Chip Market size is expected to reach $815.6 million by 2028, rising at a market growth of 30.2% CAGR during the forecast period.
The Heart on chip market is exhibiting a CAGR of 29.9% during (2022 - 2028). Replicating in vivo cardiac tissue settings has proven difficult in the past due to problems in simulating contractility and electrical responses. Such characteristics would significantly improve the precision of in vitro experiments. In vitro investigations on cardiomyocytes that generate the electrical signals that control heartbeat, have previously benefited from microfluidics.
The North America market dominated the Global Lung on chip Market by Region in 2021; thereby, achieving a market value of $94.9 Million by 2028. The Europe market is poised to grow at a CAGR of 28.6% during (2022 - 2028). Additionally, The Asia Pacific market would witness a CAGR of 30.2% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/organ-on-chip-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AxoSim, Inc., Visikol, Inc., CN Bio Innovations Limited., Elveflow (Elvesys Group), Emulate, Inc., Insphero AG, Mimetas B.V., Nortis Inc., Organovo Holdings, Inc. and TARA Biosystems, Inc.
By Type
By Geography
Companies Profiled
Unique Offerings 
